FAM219A

Summary

FAM219A (family with sequence similarity 219 member A, HGNC:19920) is a protein-coding gene on chromosome 9p13.3, encoding Protein FAM219A (Q8IW50).

The protein encoded by this gene has homologs that have been identified in mouse, macaque, etc organisms. Multiple alternatively spliced transcript variants that encode different protein isoforms have been described for this gene.

Source: NCBI Gene 203259 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 23 total
• MANE Select transcript: NM_001184940

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19920
Approved symbol	FAM219A
Name	family with sequence similarity 219 member A
Location	9p13.3
Locus type	gene with protein product
Status	Approved
Aliases	bA573M23.5, FLJ39031
Ensembl gene	ENSG00000164970
Ensembl biotype	protein_coding
Entrez	203259

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 14 protein_coding

ENST00000297620, ENST00000379078, ENST00000379080, ENST00000379081, ENST00000379084, ENST00000379087, ENST00000379089, ENST00000422409, ENST00000445726, ENST00000651358, ENST00000858746, ENST00000858747, ENST00000921867, ENST00000953321

RefSeq mRNA: 6 — MANE Select: NM_001184940 NM_001184940, NM_001184941, NM_001184942, NM_001184943, NM_001184945, NM_147202

CCDS: CCDS55304, CCDS6556

Canonical transcript exons

ENST00000651358 — 6 exons

Exon	Start	End
ENSE00003889999	34405865	34405964
ENSE00003890056	34401666	34401720
ENSE00003891020	34458204	34458570
ENSE00003894181	34402705	34402807
ENSE00003895097	34398184	34401122
ENSE00003895480	34402387	34402467

Expression profiles

Bgee: expression breadth ubiquitous, 245 present calls, max score 97.39.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 30.6398 / max 312.1524, expressed in 1811 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
100511	27.5973	1810
100509	2.2655	1120
100510	0.7770	413

Top tissues by expression

257 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	97.39	gold quality
superior vestibular nucleus	UBERON:0007227	96.75	gold quality
medulla oblongata	UBERON:0001896	96.36	gold quality
ventral tegmental area	UBERON:0002691	96.27	gold quality
inferior vagus X ganglion	UBERON:0005363	96.07	gold quality
pons	UBERON:0000988	96.01	gold quality
hypothalamus	UBERON:0001898	95.91	gold quality
midbrain	UBERON:0001891	95.81	gold quality
prefrontal cortex	UBERON:0000451	95.76	gold quality
substantia nigra	UBERON:0002038	95.71	gold quality
dorsal plus ventral thalamus	UBERON:0001897	95.66	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.43	gold quality
spinal cord	UBERON:0002240	95.41	gold quality
amygdala	UBERON:0001876	95.39	gold quality
substantia nigra pars compacta	UBERON:0001965	95.38	gold quality
lateral nuclear group of thalamus	UBERON:0002736	95.25	gold quality
parietal lobe	UBERON:0001872	95.23	gold quality
right frontal lobe	UBERON:0002810	95.21	gold quality
subthalamic nucleus	UBERON:0001906	95.18	gold quality
anterior cingulate cortex	UBERON:0009835	95.18	gold quality
substantia nigra pars reticulata	UBERON:0001966	95.11	gold quality
postcentral gyrus	UBERON:0002581	95.03	gold quality
frontal cortex	UBERON:0001870	95.00	gold quality
putamen	UBERON:0001874	94.97	gold quality
neocortex	UBERON:0001950	94.76	gold quality
temporal lobe	UBERON:0001871	94.27	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.23	gold quality
ganglionic eminence	UBERON:0004023	94.14	gold quality
embryo	UBERON:0000922	94.13	gold quality
superior frontal gyrus	UBERON:0002661	94.11	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.48

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

132 targeting FAM219A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-3162-3P	100.00	65.37	363
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-12119	99.87	68.35	1653

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	fam219ab	ENSDARG00000013813
danio_rerio	fam219aa	ENSDARG00000016396
mus_musculus	Fam219a	ENSMUSG00000028439
rattus_norvegicus	Fam219a	ENSRNOG00000039559

Paralogs (1): FAM219B (ENSG00000178761)

Protein

Protein identifiers

Protein FAM219A — Q8IW50 (reviewed: Q8IW50)

All UniProt accessions (8): A0A0A0MRV9, A0A0A0MRW0, A0A0A0MRW1, A0A0A0MRW2, A0A0A0MRW3, Q8IW50, Q5T586, Q5T593

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the FAM219 family.

Isoforms (7)

UniProt ID	Names	Canonical?
Q8IW50-1	1	yes
Q8IW50-2	2
Q8IW50-3	3
Q8IW50-4	4
Q8IW50-5	5
Q8IW50-6	6
Q8IW50-7	7

RefSeq proteins (6): NP_001171869, NP_001171870, NP_001171871, NP_001171872, NP_001171874, NP_671735 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029339	FAM219	Family

Pfam: PF15260

UniProt features (18 total): modified residue 7, splice variant 5, compositionally biased region 3, chain 1, region of interest 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IW50-F1	63.93	0.04

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 115, 122, 1, 47, 72, 102, 113

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 112 (showing top): GCM_MAP4K4, E2F_Q4_01, GGTGTGT_MIR329, GCM_PTPRD, AAGCCAT_MIR135A_MIR135B, AACYNNNNTTCCS_UNKNOWN, PAX8_B, BRN2_01, TGCTGAY_UNKNOWN, chr9p13, TGACATY_UNKNOWN, ATF3_Q6, PU1_Q6, CCAGGTT_MIR490, GCM_CALM1

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

294 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FAM219A	RPP25L	Q8N5L8	654
FAM219A	DCTN3	O75935	584
FAM219A	ZNF511	Q8NB15	566
FAM219A	SPMIP6	Q8NCR6	563
FAM219A	ENHO	Q6UWT2	546
FAM219A	ZFAND2B	Q8WV99	532
FAM219A	SPATA31F1	Q6ZU69	528
FAM219A	DNAI1	Q9UI46	497
FAM219A	CFAP95	Q5VTT2	479
FAM219A	LRRC39	Q96DD0	470
FAM219A	ARID3C	A6NKF2	448
FAM219A	CFAP161	Q6P656	434
FAM219A	MYORG	Q6NSJ0	424
FAM219A	TMEM215	Q68D42	418
FAM219A	CELA2B	P08218	400
FAM219A	WDR83OS	Q9Y284	400

IntAct

22 interactions, top by confidence:

A	B	Type	Score
RABGGTB	PIPSL	psi-mi:“MI:0914”(association)	0.530
GPR37	ATE1	psi-mi:“MI:0914”(association)	0.530
FAM219A	OBSL1	psi-mi:“MI:0914”(association)	0.530
FAM219A	CSNK1G1	psi-mi:“MI:0915”(physical association)	0.370
FAM219A	NIPSNAP3A	psi-mi:“MI:0915”(physical association)	0.370
SPRY2	FAM219A	psi-mi:“MI:0915”(physical association)	0.370
CHRNA4	TMEM223	psi-mi:“MI:0914”(association)	0.350
RUSF1	TMEM120B	psi-mi:“MI:0914”(association)	0.350
GORASP1	RTCA	psi-mi:“MI:0914”(association)	0.350
KCNE3	PIK3R2	psi-mi:“MI:0914”(association)	0.350
FAM219A	NBN	psi-mi:“MI:0914”(association)	0.350
PDE6D	SUN1	psi-mi:“MI:0914”(association)	0.350
FAM219A	H1-1	psi-mi:“MI:0914”(association)	0.350
TMEM17	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
TGOLN2	BLTP3B	psi-mi:“MI:2364”(proximity)	0.270
TGOLN2	TRAPPC13	psi-mi:“MI:2364”(proximity)	0.270
	ARHGAP32	psi-mi:“MI:2364”(proximity)	0.270
FAM219A	PDE6D	psi-mi:“MI:0915”(physical association)	0.000
FAM219A	POLA2	psi-mi:“MI:0915”(physical association)	0.000
FAM219A	WWC1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (95): FAM219A (Affinity Capture-MS), GATAD2A (Affinity Capture-MS), MBD3 (Affinity Capture-MS), FBXO10 (Affinity Capture-MS), MTA2 (Affinity Capture-MS), MTA3 (Affinity Capture-MS), MTA1 (Affinity Capture-MS), UBR3 (Affinity Capture-MS), ATE1 (Affinity Capture-MS), MRE11A (Affinity Capture-MS), OBSL1 (Affinity Capture-MS), RAD50 (Affinity Capture-MS), NBN (Affinity Capture-MS), WDFY1 (Affinity Capture-MS), MARS2 (Affinity Capture-MS)

ESM2 similar proteins: A0A088MLT8, A2AQ19, A4FV29, A4IFK9, B3KU38, O14795, O70166, O93388, O95983, P21818, P31395, P50751, P54227, P55821, P63042, P63043, Q09001, Q09002, Q09004, Q09006, Q2KJ58, Q32L68, Q4KUS2, Q4R4N5, Q5F3L9, Q5FVJ5, Q5PSV4, Q5R4C5, Q5R562, Q5R8C6, Q5RAD5, Q62768, Q6GQB5, Q8IVM0, Q8IW50, Q8TBN0, Q8VDV3, Q90987, Q92541, Q93045

Diamond homologs: Q14DQ1, Q5XKK7, Q6DC60, Q8IW50, Q9BGQ5, Q9D772

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

23 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	16
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1219 predictions. Top by Δscore:

Variant	Effect	Δscore
9:34401118:ATCTG:A	acceptor_gain	1.0000
9:34401120:CTG:C	acceptor_gain	1.0000
9:34401121:TG:T	acceptor_gain	1.0000
9:34401121:TGCTG:T	acceptor_loss	1.0000
9:34401122:GCTG:G	acceptor_loss	1.0000
9:34401123:C:CC	acceptor_gain	1.0000
9:34401124:T:C	acceptor_loss	1.0000
9:34401125:G:C	acceptor_gain	1.0000
9:34401130:C:CT	acceptor_gain	1.0000
9:34401660:GCTCA:G	donor_loss	1.0000
9:34401661:CTCA:C	donor_loss	1.0000
9:34401662:TCA:T	donor_loss	1.0000
9:34401663:CA:C	donor_loss	1.0000
9:34401664:A:T	donor_loss	1.0000
9:34401665:C:T	donor_loss	1.0000
9:34401718:TCG:T	acceptor_gain	1.0000
9:34401719:CGC:C	acceptor_gain	1.0000
9:34401725:CCA:C	acceptor_gain	1.0000
9:34401726:C:T	acceptor_gain	1.0000
9:34401726:CA:C	acceptor_gain	1.0000
9:34401727:A:AC	acceptor_gain	1.0000
9:34401727:A:C	acceptor_gain	1.0000
9:34401727:A:T	acceptor_gain	1.0000
9:34402383:ACAC:A	donor_loss	1.0000
9:34402384:CA:C	donor_loss	1.0000
9:34402385:A:AT	donor_loss	1.0000
9:34402463:CCAGC:C	acceptor_gain	1.0000
9:34402464:CAGC:C	acceptor_gain	1.0000
9:34402464:CAGCC:C	acceptor_gain	1.0000
9:34402466:GC:G	acceptor_gain	1.0000

AlphaMissense

1223 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:34401040:A:G	L161P	1.000
9:34401040:A:T	L161H	1.000
9:34401046:A:G	L159P	1.000
9:34401046:A:T	L159Q	1.000
9:34401059:C:G	D155H	1.000
9:34401070:T:A	D151V	1.000
9:34401071:C:G	D151H	1.000
9:34401073:A:G	L150S	1.000
9:34401080:A:C	Y148D	1.000
9:34401082:C:A	G147V	1.000
9:34401083:C:A	G147C	1.000
9:34401083:C:G	G147R	1.000
9:34401085:T:A	D146V	1.000
9:34401086:C:G	D146H	1.000
9:34401091:A:G	L144P	1.000
9:34401094:A:G	L143P	1.000
9:34401094:A:T	L143Q	1.000
9:34401037:A:C	I162S	0.999
9:34401037:A:G	I162T	0.999
9:34401037:A:T	I162N	0.999
9:34401040:A:C	L161R	0.999
9:34401042:G:C	D160E	0.999
9:34401042:G:T	D160E	0.999
9:34401043:T:A	D160V	0.999
9:34401043:T:C	D160G	0.999
9:34401043:T:G	D160A	0.999
9:34401044:C:G	D160H	0.999
9:34401046:A:C	L159R	0.999
9:34401050:C:G	D158H	0.999
9:34401058:T:A	D155V	0.999

dbSNP variants (sampled 300 via entrez): RS1000052392 (9:34420311 G>A,C), RS1000095707 (9:34410228 G>A), RS1000321332 (9:34426764 G>A,T), RS1000324479 (9:34430363 T>TACAAA), RS1000369311 (9:34457727 T>C), RS1000385702 (9:34447243 T>C), RS1000398296 (9:34430112 G>A), RS1000538188 (9:34436887 T>C), RS1000549288 (9:34409944 G>T), RS1000551047 (9:34420629 G>A), RS1000580433 (9:34433665 T>C), RS1000650214 (9:34425322 A>G), RS1000877292 (9:34403593 C>G,T), RS1000889039 (9:34399792 G>A), RS1000953618 (9:34442755 A>G)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:167320, MIM:108120, MIM:230400, MIM:602875, MIM:613954, MIM:615923, MIM:244400

GenCC curated gene-disease

Mondo (7): inclusion body myopathy with Paget disease of bone and frontotemporal dementia (MONDO:0000507), arthrogryposis, distal, type 1A (MONDO:0007157), classic galactosemia (MONDO:0009258), acromesomelic dysplasia 1, Maroteaux type (MONDO:0011275), frontotemporal dementia and/or amyotrophic lateral sclerosis 6 (MONDO:0013501), tall stature-scoliosis-macrodactyly of the great toes syndrome (MONDO:0014401), primary ciliary dyskinesia (MONDO:0016575)

Orphanet (9): Distal arthrogryposis type 1 (Orphanet:1146), Primary ciliary dyskinesia (Orphanet:244), Frontotemporal dementia with motor neuron disease (Orphanet:275872), Tall stature-long halluces-multiple extra-epiphyses syndrome (Orphanet:329191), Galactosemia (Orphanet:352), Acromesomelic dysplasia, Maroteaux type (Orphanet:40), Inclusion body myopathy with Paget disease of bone and frontotemporal dementia (Orphanet:52430), Classic galactosemia (Orphanet:79239), Amyotrophic lateral sclerosis (Orphanet:803)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D002925	Ciliary Motility Disorders	C08.200; C09.150; C16.131.077.245.500; C16.320.184.500
D007619	Kartagener Syndrome	C08.127.384.500; C08.200.531; C08.695.501; C09.150.531; C14.240.400.280.500; C14.280.400.280.500; C16.131.077.245.500.531; C16.131.240.400.280.500; C16.131.740.501; C16.131.810.250.500; C16.320.184.500.531; C16.320.480
C535661	Acromesomelic dysplasia, Maroteaux type (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	4
sodium arsenite	affects cotreatment, increases abundance, increases expression	2
Estradiol	affects cotreatment, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Cyclosporine	increases expression	2
Cadmium Chloride	increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
lead acetate	increases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
cobaltous chloride	increases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
aflatoxin B2	increases methylation	1
cupric chloride	increases expression	1
coumarin	increases phosphorylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
NSC 689534	affects binding, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Bortezomib	increases expression	1
Irinotecan	decreases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Acetaminophen	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Atrazine	increases expression	1

Clinical trials (associated diseases)

84 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05418829	PHASE3	UNKNOWN	AT-007 in Adult Subjects With Classic Galactosemia (CG)
NCT03580122	PHASE2	COMPLETED	The Effect of Arginine on Classic Galactosemia
NCT02871778	PHASE2	COMPLETED	Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
NCT07318974	PHASE2	ACTIVE_NOT_RECRUITING	Melatonin Therapy for Improving ICSI Outcomes in Women With Diminished Ovarian Reserve
NCT05737485	PHASE1	COMPLETED	Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects
NCT06600425	PHASE1	COMPLETED	A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD
NCT06633757	PHASE1	COMPLETED	Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance
NCT01353430	Not specified	RECRUITING	Characterization of Inclusion Body Myopathy Associated With Paget’s Disease of Bone and Frontotemporal Dementia (IBMPFD)
NCT01793168	Not specified	RECRUITING	Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
NCT04823143	Not specified	COMPLETED	Natural History Study of Patients With VCP-related Disease
NCT01144741	Not specified	TERMINATED	Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome
NCT05393375	Not specified	COMPLETED	Arthrogryposis Multiplex Congenita in Pediatric Age: Correlation Between MUScular MRI and Functional Evaluation
NCT05673265	Not specified	UNKNOWN	Pediatric and Adult Registry for Patients With ARThrogryposis
NCT06130592	Not specified	UNKNOWN	Technical Feasibility Study of Ultrasound Muscle Imaging in Antenatal Ultrasound
NCT07360574	Not specified	NOT_YET_RECRUITING	Piezo2-related Arthrogryposis & physiopathOLOgy 3
NCT04902781	PHASE2/PHASE3	COMPLETED	Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia
NCT04117711	PHASE1/PHASE2	COMPLETED	Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia
NCT03838016	EARLY_PHASE1	COMPLETED	Preventing Speech and Language Disorders in Children With Classic Galactosemia
NCT04901715	EARLY_PHASE1	COMPLETED	Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype
NCT00005650	Not specified	COMPLETED	Genetic Study of Patients With Primary Ciliary Dyskinesia
NCT00323167	Not specified	COMPLETED	Rare Genetic Disorders of the Breathing Airways
NCT00368446	Not specified	COMPLETED	Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease
NCT00450918	Not specified	COMPLETED	Evaluating Progression of and Diagnostic Tools for Primary Ciliary Dyskinesia in Children and Adolescents
NCT00608556	Not specified	COMPLETED	Dyskinesia, Heterotaxy and Congenital Heart Disease
NCT00686309	Not specified	UNKNOWN	Comparison of On-line and Off-line Measurements of Exhaled Nitric Oxide (NO)
NCT00722878	Not specified	COMPLETED	Long-term Lung Function and Disease Progression in Children With Early Onset Primary Ciliary Dyskinesia Lung Disease
NCT00739817	Not specified	UNKNOWN	Screening for Primary Ciliary Dyskinesia Using Nasal Nitric Oxide
NCT00783887	Not specified	COMPLETED	Diagnosis of Primary Ciliary Dyskinesia
NCT00807482	Not specified	RECRUITING	Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease
NCT01070914	Not specified	UNKNOWN	Early Detection and Characterization of Primary Ciliary Dyskinesia
NCT01155115	Not specified	COMPLETED	Inflammatory and Microbiologic Markers in Sputum: Comparing Cystic Fibrosis With Primary Ciliary Dyskinesia
NCT01246258	Not specified	COMPLETED	Otolith Function in Patients With Primary Ciliary Dyskinesia
NCT01929356	Not specified	RECRUITING	Chest Physiotherapy and Lung Function in Primary Ciliary Dyskinesia
NCT02389049	Not specified	COMPLETED	Genetics of Primary Ciliary Dyskinesia
NCT02419365	Not specified	RECRUITING	International Primary Ciliary Dyskinesia (PCD) Registry
NCT02699177	Not specified	UNKNOWN	In Vivo Measurements of Nasal Ciliary Beat Frequency by Using Interferometry
NCT02704455	Not specified	NOT_YET_RECRUITING	Registry Study on Primary Ciliary Dyskinesia in Chinese Children
NCT03271840	Not specified	COMPLETED	Registry for Primary Ciliary Dyskinesia
NCT03279965	Not specified	UNKNOWN	MRI in Cystic Fibrosis and Primary Ciliary Dyskinesia
NCT03320382	Not specified	UNKNOWN	Multiple Breath Washout, a Clinimetric Dataset